Working Up Group 4 Equivocal HER2 Samples Tested by Fluorescence in Situ Hybridization in a Reference Laboratory Setting: Past, Present, and Future

This publication has 9 references indexed in Scilit:

• Comparison between digital image analysis and visual assessment of immunohistochemical HER2 expression in breast cancer
  Pathology - Research and Practice, 2018
• Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
  Journal of Clinical Oncology, 2018
• Change in Pattern of HER2 Fluorescent in Situ Hybridization (FISH) Results in Breast Cancers Submitted for FISH Testing: Experience of a Reference Laboratory Using US Food and Drug Administration Criteria and American Society of Clinical Oncology and College of American Pathologists Guidelines
  Journal of Clinical Oncology, 2016
• The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
  Nature, 2012
• Predictability of Adjuvant Trastuzumab Benefit in N9831 Patients Using the ASCO/CAP HER2-Positivity Criteria
  JNCI: Journal of the National Cancer Institute, 2011
• American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer
  Journal of Clinical Oncology, 2007
• Diagnostic Evaluation of HER-2 as a Molecular Target: An Assessment of Accuracy and Reproducibility of Laboratory Testing in Large, Prospective, Randomized Clinical Trials
  Clinical Cancer Research, 2005
• Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
  New England Journal of Medicine, 2001
• DNA flow cytometry and prognostic factors in 1331 frozen breast cancer specimens
  Cancer, 1988